5570-18-3Relevant academic research and scientific papers
Asymmetric synthesis of an axially chiral antimitotic biaryl via an atropo-enantioselective Suzuki cross-coupling
Herrbach, Audrey,Marinetti, Angela,Baudoin, Olivier,Guenard, Daniel,Gueritte, Francoise
, p. 4897 - 4905 (2003)
A catalytic asymmetric synthesis of the axially chiral bridged biaryl (-)-2, a structural analogue of natural (-)-rhazinilam possessing original antimitotic properties, is described. The key step is an intermolecular asymmetric Suzuki coupling, furnishing the nonbridged biaryl (-)-6, precursor of (-)-2, with up to 40% ee using binaphthyl ligand 7a. Various known or new binaphthyl and ferrocenyl phosphines as well as phosphetanes were screened as ligands in this reaction, the conditions of which were optimized. The comparison with another Suzuki coupling system showed that 7a is the most versatile ligand described to date for this type of transformation. This work gives the first application of the asymmetric Suzuki coupling to a biologically relevant target.
A compound with anti-tumor activity of the multitarget kinase inhibitor and its preparation method
-
Paragraph 0063-0064, (2017/04/14)
The invention relates to the technical field of medicine, and relates to a type of compounds with antitumor activities, and a preparation method and an application thereof. The compounds have a structural general formula represented below. R1 is alkyl group, heterocyclic group, substituted phenyl group, substituted alicyclic group, or aliphatic heterocyclic group, wherein the substituent is 2,3-ethylenedioxy, 3,4-ethylenedioxy, 2,3-methylenedioxy, or 3,4-methylenedioxy; or all-site-substituted hydrogen, alkyl, alkoxy, halogen, amino, hydroxyl, trifluoromethyl, formate, and the like. R2 is heterocyclic group or substituted phenyl group, wherein the phenyl substituent is 2,3-ethylenedioxy, 3,4-ethylenedioxy, 2,3-methylenedioxy, or 3,4-methylenedioxy; or all-site-substituted hydrogen, alkyl, alkoxy, halogen, amino, hydroxyl, trifluoromethyl, formate, and the like. The compounds provided by the invention have substantial tumor cytotoxic effect and broad-spectrum kinase inhibitory activity, and can be used in preparing antitumor medicines.
Indole and quinoline derivatives and its preparation method and application
-
Paragraph 0183; 0184, (2017/02/28)
The invention provides an indoloquinoline derivative, a preparation method and application thereof in preparing antitumor drugs and antiviral drugs. The chemical structure of the indoloquinoline derivative is shown as a formula I. Experiments show that a partly-boric-acid-modified indoloquinoline derivative and a non-boric-acid-modified indoloquinoline derivative have strong inhibition effect on various tumor cell strains, thereby being capable of being used for preparation of the antitumor drugs, and have strong antiviral activity, thereby being capable of being used for preparation of the antiviral drugs.
Novel inhibitors of bacterial biofilms and related methods
-
Paragraph 0184-0185, (2014/05/06)
Multi-cyclic compounds of chemical structure represented by formula given below and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.
Process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters
-
Paragraph 0053; 0056; 0058, (2014/11/27)
The present invention relates to a process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters of formula (I) in high yields The claimed process uses diarylketal formula (V) to generate an arylbromid of formula (III) in which the amino-group is protected as bisarylmethylidenimino-group:
PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS
-
Page/Page column 15; 16; 17; 18, (2014/12/09)
The present invention relates to a process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters thereof of formula (I) in high yield. The claimed process uses diarylketal formula (V) to generate an arylbromide of formula (III) in which the amino-group is protected as bisarylmethylidenimino-group, which is then transformed into a formula (I) compound.
Inhibitors of bacterial biofilms and related methods
-
Page/Page column 116, (2012/12/13)
Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.
1,3,5-Tris(2′-aminophenyl)benzene: A novel platform for molecular receptors
Pia?tek, Piotr,S?omiany, Norbert
, p. 2027 - 2030 (2008/02/05)
The synthesis of a novel, rigid, aromatic platform for molecular receptors is described. 1,3,5-Tris(2′-aminophenyl)benzene was prepared via Suzuki-Miyaura cross-coupling reactions of 2-aminophenylboronic acid with 1,3,5-triiodobenzene in the presence of Ba(OH)2, Pd(OAc)2 and (2-biphenyl)dicyclohexylphosphine. Alternatively, one-pot borylation of 2-bromoaniline and cross-coupling of the resulting boronate ester with 1,3,5-triiodobenzene was investigated. Georg Thieme Verlag Stuttgart.
Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3
-
Page/Page column 47, (2008/06/13)
Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.
DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
-
Page 34, (2008/06/13)
The present invention relates to novel diarylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.
